rAAV Vector Gene Delivery for Pompe Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuromuscular and lysosomal storage diseases, such as Pompe disease, lack effective methods for long-term restoration of neuromuscular junction integrity and sustained expression of therapeutic genes, particularly in skeletal muscle and the central nervous system.
Innovation Solution
The use of recombinant adeno-associated virus (rAAV) vectors, specifically pseudotyped with serotypes like AAV2/1, AAV2/8, and AAV2/9, to deliver therapeutic genes encoding acid alpha-glucosidase (GAA) to various tissues, including skeletal muscle and the CNS, via intravenous, intramuscular, or intrathecal routes, facilitating retrograde transport and sustained expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If traditional gene delivery methods are used, then therapeutic genes can be delivered to target tissues, but long-term sustained expression and restoration of neuromuscular junction integrity cannot be achieved
Solution Approach 1:
The patent employs rAAV vectors as intermediary carriers to deliver therapeutic genes to target tissues. These vectors serve as mediators that enable sustained gene expression by protecting the genetic material and facilitating its integration into host cells, thereby achieving both long-term expression and reliable neuromuscular junction restoration
Solution Approach 2:
The patent utilizes different rAAV serotypes (1, 8, 9, rh10) with distinct biological properties to optimize gene delivery. By changing the serotype parameter, the system achieves enhanced transduction efficiency, prolonged expression duration, and improved reliability of neuromuscular function restoration in various tissue types
2Duration of action of moving object
If rAAV vectors are used to deliver therapeutic genes to skeletal muscle and CNS, then long-term sustained expression is achieved, but delivery to specific tissues requires complex administration routes
Solution Approach 1:
The patent develops rAAV vector systems with broad tropism that can deliver therapeutic genes to multiple target tissues (skeletal muscle, heart, CNS) through various administration routes. This multi-functionality allows a single vector platform to address different tissue targets, simplifying the overall treatment approach while maintaining sustained expression
Solution Approach 2:
The patent employs different rAAV serotypes segmented for specific tissue tropisms (e.g., serotype 1 for muscle, serotype 9 for CNS). This segmentation allows optimization of gene delivery to specific tissues while maintaining the ability to use systemic administration routes, reducing operational complexity
3Reliability
If high doses of therapeutic gene are delivered to achieve sufficient expression levels, then disease symptoms improve, but vector toxicity and immune responses increase
Solution Approach 1:
The patent optimizes vector dosage and serotype selection to achieve therapeutic efficacy at reduced doses. By changing parameters such as serotype (1, 8, 9, rh10) and administration route, the system enhances transduction efficiency, allowing lower doses that minimize toxicity and immune responses while maintaining effective disease treatment
Solution Approach 2:
The patent uses recombinant AAV vectors that contain only the essential therapeutic gene without viral replication functions. This copied, simplified genetic construct achieves therapeutic expression levels with reduced immunogenicity compared to full viral genomes, lowering harmful effects while maintaining efficacy
Data Source
AI summary
The present invention provides compositions and methods of use pertaining to rAAV-mediated delivery of therapeutically effective molecules for treatment of diseases such as Pompe disease. These compositions in combination with various routes and methods of administration result in targeted expression of therapeutic molecules in specific organs, tissues and cells.